Today's Stocks Driving Success For The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 14 points (-0.1%) at 16,929 as of Tuesday, June 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 966 issues advancing vs. 1,989 declining with 165 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is down 0.2%. Top gainers within the sector include Illumina ( ILMN), up 1.4%, Bristol-Myers Squibb Company ( BMY), up 0.7%, Teva Pharmaceutical Industries ( TEVA), up 0.6% and Gilead ( GILD), up 0.6%. On the negative front, top decliners within the sector include CR Bard ( BCR), down 3.9%, Jazz Pharmaceuticals ( JAZZ), down 3.6%, Actavis ( ACT), down 1.7%, Biogen Idec ( BIIB), down 1.6% and Regeneron Pharmaceuticals ( REGN), down 1.6%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector higher today. As of noon trading, Novo Nordisk A/S is up $1.09 (2.5%) to $44.29 on average volume. Thus far, 438,130 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $43.93-$44.50 after having opened the day at $43.94 as compared to the previous trading day's close of $43.20.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $119.7 billion and is part of the drugs industry. Shares are up 16.9% year-to-date as of the close of trading on Monday. Currently there are 2 analysts who rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Isis Pharmaceuticals ( ISIS) is up $1.79 (5.8%) to $32.90 on heavy volume. Thus far, 2.6 million shares of Isis Pharmaceuticals exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $32.30-$33.70 after having opened the day at $32.33 as compared to the previous trading day's close of $31.11.

Isis Pharmaceuticals, Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. Isis Pharmaceuticals has a market cap of $3.6 billion and is part of the drugs industry. Shares are down 21.9% year-to-date as of the close of trading on Monday. Currently there are 5 analysts who rate Isis Pharmaceuticals a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Isis Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Isis Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Novartis ( NVS) is up $1.08 (1.2%) to $90.19 on heavy volume. Thus far, 1.6 million shares of Novartis exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $90.01-$90.38 after having opened the day at $90.26 as compared to the previous trading day's close of $89.11.

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. Novartis has a market cap of $217.8 billion and is part of the drugs industry. Shares are up 10.9% year-to-date as of the close of trading on Monday. Currently there are 5 analysts who rate Novartis a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Novartis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes